Psilocybin Outperforms SSRIs in Long-Term Depression Treatment
A recent study from Imperial College London has revealed a new potential treatment for major depression, psilocybin.
Category
Psychedelics
8 stories in this category.
Psychedelics Company Secures $6M For Mental Health Treatment
In addition to the raise, Dr. Rick Doblin of MAPS has joined Numinus as an unpaid strategic advisor.
US FDA Greenlights MDMA Therapy for PTSD Review
The FDA has accepted Lykos Therapeutics' MDMA-assisted therapy application and could transform mental health treatment.
Veterans Affairs Department Approves Psychedelics-Based Treatments for Mental Health
The US Department of Veteran Affairs will fund research for psychedelics-based therapies for the first time.
Psychedelic Biotech Raises $100M for MDMA-based PTSD Treatment
Following their submission for FDA approval for MDMA-based therapy in December, MAPS has rebranded to Lykos Therapeutics.
MDMA is the First Psychedelic Drug Submission Seeking FDA Approval
This marks a significant moment in the widespread acceptance of using psychedelics for therapeutic use.
Steve Cohen's Millions Propel Psychedelic Research Therapy
Steve Cohen's investment boosts psychedelic research in biopharma, with top billionaires reshaping mental health care.
Ex-Tesla Director Gracias Powers Harvard’s $16M Psychedelic Renaissance
Harvard explores psychedelics with $16M from ex-Tesla director Antonio Gracias.